SCHEMBL29675862

SCHEMBL29675862

N#Cc1ccc(C(=O)Nc2cncc(-c3ccnc(-c4ncc(-c5ccccc5)[nH]4)c3)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.48
PDGFRB P09619 1/20 0.48
BCR P11274 1/20 0.48
PDGFRA P16234 1/20 0.48
PRKCA P17252 1/20 0.48
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
CLK2 P49760 6/20 0.46
DYRK1A Q13627 6/20 0.46
CLK3 P49761 5/20 0.46
NPY5R Q15761 1/20 0.46
MAPT P10636 3/20 0.45
GSK3B P49841 2/20 0.45
WNT1 P04628 2/20 0.44
BACE1 P56817 2/20 0.42
KCNH2 Q12809 1/20 0.42
SCN10A Q9Y5Y9 1/20 0.42
PPARG P37231 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19065223 1.00 ABL1 (0.48) ABL1PDGFRBBCRPDGFRAPRKCA
SCHEMBL29675315 0.92 GRM5 (0.49) ABL1CLK2DYRK1ACLK3MAPT
SCHEMBL19065248 0.92 GRM5 (0.49) ABL1CLK2DYRK1ACLK3MAPT
SCHEMBL19065434 0.92 CLK2 (0.52) CLK2DYRK1ACLK3NPY5RMAPT
SCHEMBL29675461 0.92 CLK2 (0.52) CLK2DYRK1ACLK3NPY5RMAPT
SCHEMBL29675481 0.88 BCHE (0.48) CYP11B1CYP11B2CLK2DYRK1ACLK3
SCHEMBL19066087 0.88 BCHE (0.48) CYP11B1CYP11B2CLK2DYRK1ACLK3
SCHEMBL19065218 0.84 NPY5R (0.48) CLK2DYRK1ACLK3NPY5RMAPT
SCHEMBL29675270 0.84 MAPT (0.48) CLK2DYRK1ACLK3MAPTGSK3B
SCHEMBL19065314 0.84 MAPT (0.48) CLK2DYRK1ACLK3MAPTGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3792256-B1 PYRIDINE COMPOUNDS AS PI3K-GAMMA INHIBITORS INCYTE CORP (US) 2024-10-23 EP claimed
US-11952367-B2 Pyridine and pyridimine compounds as PI3K-gamma inhibitors INCYTE CORPORATION (US) 2024-04-09 US disclosed
US-20220227736-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION 2022-07-21 US disclosed
US-11352340-B2 Pyridine and pyridimine compounds as PI3K-gamma inhibitors INCYTE CORPORATION (US) 2022-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220227736-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS PIK3CG, PIK3CD, PIK3CB ABL1 352/4885PDGFRB 109/4885BCR 600/4885
US-11352340-B2 Pyridine and pyridimine compounds as PI3K-gamma inhibitors PIK3CG, PIK3CD, PIK3CB ABL1 352/4885PDGFRB 109/4885BCR 600/4885
US-11952367-B2 Pyridine and pyridimine compounds as PI3K-gamma inhibitors PIK3CG, PIK3CD, PIK3CB ABL1 352/4885PDGFRB 109/4885BCR 600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.